Latest Conference Articles

June 3rd 2017, 12:33am

ASCO Annual Meeting

The rate of severe long-term side effects caused by treatments for childhood cancers is dropping over time, according to findings from a retrospective analysis of 23,600 survivors enrolled in the Childhood Cancer Survivor Study.

June 3rd 2017, 12:20am

ASCO Annual Meeting

Results from a large, phase III trial showed that a single radiation treatment relieves symptoms of spinal cord compression in patients with advanced cancer as effectively as a multifractional course of radiotherapy (RT)

June 3rd 2017, 12:09am

ASCO Annual Meeting

Psychological intervention can substantially lower fear of cancer recurrence in survivors, improving their quality of life, anxiety, and cancer-specific distress, according to a phase II randomized clinical trial presented at the 2017 ASCO Annual Meeting.

June 2nd 2017, 9:06pm

ASCO Annual Meeting

Frontline treatment with ribociclib plus letrozole improved progression-free survival by 9.3 months compared with letrozole plus placebo for patients with postmenopausal HR-positive, HER2-negative advanced breast cancer.

May 18th 2017, 1:13am

ASCO Annual Meeting

Adjuvant gefitinib reduced the risk of disease recurrence by 40% versus standard chemotherapy in patients with EGFR-positive non­–small cell lung cancer, study reports.

May 18th 2017, 12:58am

ASCO Annual Meeting

Patients with stage III colorectal cancer who maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors experienced a 42% lower chance of death and a trend toward reduced cancer recurrence.

May 18th 2017, 12:44am

ASCO Annual Meeting

The efficacy of the human papillomavirus vaccine continues to be impressive, with newly reported findings showing that it reduced the prevalence of high-risk oral HPV infections by 88% in young adults who had at least 1 dose of the vaccine; however, low vaccine uptake remains a concern.

May 18th 2017, 12:35am

ASCO Annual Meeting

More Stage I cancers were diagnosed after the passage of the Affordable Care Act within five screenable disease types than were diagnosed before ACA implementation.

May 18th 2017, 12:19am

ASCO Annual Meeting

Findings of a new prospective study suggest that eating tree nuts like almonds, walnuts, and pecans can improve overall survival and reduce the risk of recurrence in patients with colon cancer.

May 17th 2017, 11:32pm

ASCO Annual Meeting

Treatment with adjuvant capecitabine improved overall survival by 15 months compared with observation alone for patients with macroscopically resected biliary tract cancer, according to findings from the phase III BILCAP study released in advance of the 2017 ASCO Annual Meeting.

May 10th 2017, 9:57pm

State of the Science Summit on Hematologic Malignancies

Ellen K. Ritchie, MD, highlights current and emerging novel treatments, and the possibility of using immunotherapy to treat patients with systemic mastocytosis, advanced symptomatic hypereosinoophic disorder, myelofibrosis, and chronic myelomonocytic leukemia

May 10th 2017, 9:38pm

State of the Science Summit on Hematologic Malignancies

John P. Leonard, MD, discusses advancements across hematologic malignancies and pivotal trial data he is anticipating at the 2017 ASCO Annual Meeting.

May 10th 2017, 7:29pm

State of the Science Summit on Hematologic Malignancies

Sarah Rutherford, MD, John P. Leonard, M.D./Gwirtzman Family Research Scholar in Lymphoma , assistant professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the classification and prevalence of double-hit and double-expressor lymphomas.

May 10th 2017, 7:14pm

State of the Science Summit on Hematologic Malignancies

Gail J. Roboz, MD, discusses the recent FDA approval of midostaurin and what else is emerging in the treatment landscape in AML.

May 10th 2017, 7:10pm

State of the Science Summit on Hematologic Malignancies

Lisa Giulino Roth, MD, assistant professor of Pediatrics in Medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treating adolescent and young adult patients with Hodgkin lymphoma.

May 10th 2017, 1:03am

State of the Science Summit on Hematologic Malignancies

Ruben Niesvizky, MD, discusses some of the exciting advances, the potential of chimeric antigen receptor T-cell therapy, and emerging combination regimens on the horizon in multiple myeloma.

May 10th 2017, 12:49am

State of the Science Summit on Hematologic Malignancies

Jia Ruan, MD, PhD, associate professor of Clinical Medicine, Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the classification of T-cell lymphomas.

May 10th 2017, 12:13am

State of the Science Summit on Hematologic Malignancies

Tsiporah B. Shore, MD, associate director of the Blood and Bone Marrow Transplant Program of Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses stem cell transplantation in patients with hematologic malignancies and are of ethnic populations.

May 9th 2017, 7:13pm

AACR Annual Meeting

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of Medicine, Temple University School of Medicine, discusses whether the overall survival (OS) justifies the toxicities demonstrated in the CheckMate-067 trial for patients with melanoma.

April 23rd 2017, 1:56am

International Liver Congress

Jordi Bruix, MD, discusses the success of regorafenib in hepatocellular carcinoma and its impact on the field going forward.